At DJS we are developing novel therapeutics to treat chronic inflammatory diseases. We do this through the discovery and development of novel therapeutic monoclonal antibodies against GPCRs. Our breakthrough technology enables us to produce first-in-class antibody therapeutics to previously intractable disease targets.